Popis: |
Anna Forsythe,1 Christina S Kwon,1 Timothy Bell,2 T Alexander Smith,3 Bhakti Arondekar4 1Purple Squirrel Economics, New York, NY, USA; 2Pfizer Inc, New York, NY, USA; 3Pfizer Ltd, Walton Oaks, UK; 4Pfizer Inc, Collegeville, PA, USA Background: AML is a rapidly progressing bone marrow cancer, with poor survival rates compared to other types of leukemia. IC and NIC as well as BSC treatment options are available; however, there is scant published literature on the impact of disease and treatment on the HRQoL in patients receiving NIC.Aim: This study determined the HRQoL among NIC AML patients.Materials and methods: Embase, Medline, Cochrane database, and conference abstracts were searched using the prespecified PICOS criteria from January 2000 to November 2017 for studies reporting HRQoL and patient preference utilities in NIC AML. Studies on patients with RAEB-t MDS, randomized clinical trials (RCTs), prospective observational studies, and patient surveys were included, while systematic reviews and meta-analyses were used for bibliographic searching.Results: Thirteen records from 12 original studies were identified. These included five records from four RCTs, three prospective studies, four patient survey studies, and one cost-effectiveness analysis. At baseline, NIC AML patients had poor HRQoL scores especially in fatigue (33) and GHS (50) on a 0–100 scale, with higher scores indicating better health. Low baseline HRQoL scores, especially PF and fatigue ( |